Arecor

Arecor is a clinical-stage biotech company developing superior therapeutics that reduce treatment burden and improve outcomes for people with chronic disease. Its Arestat drug formulation platform is applied to high-value biologics, including peptides, and is licensed to pharmaceutical and biotech partners across disease areas. The pipeline includes AT278, an ultra-concentrated ultra-rapid-acting insulin designed for automated insulin delivery and partnered with Sequel Med Tech, plus next-generation oral peptide delivery aimed at the obesity market. Arecor generates license revenue from a diversified partner base and holds more than 100 granted patents in the US, Europe, and other territories.